JP2004525896A5 - - Google Patents

Download PDF

Info

Publication number
JP2004525896A5
JP2004525896A5 JP2002564525A JP2002564525A JP2004525896A5 JP 2004525896 A5 JP2004525896 A5 JP 2004525896A5 JP 2002564525 A JP2002564525 A JP 2002564525A JP 2002564525 A JP2002564525 A JP 2002564525A JP 2004525896 A5 JP2004525896 A5 JP 2004525896A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
cycloalkyl
heteroalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002564525A
Other languages
English (en)
Japanese (ja)
Other versions
JP4064818B2 (ja
JP2004525896A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2002/001106 external-priority patent/WO2002064594A2/en
Publication of JP2004525896A publication Critical patent/JP2004525896A/ja
Publication of JP2004525896A5 publication Critical patent/JP2004525896A5/ja
Application granted granted Critical
Publication of JP4064818B2 publication Critical patent/JP4064818B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002564525A 2001-02-12 2002-02-04 6−置換ピリド−ピリミジン類 Expired - Lifetime JP4064818B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26837501P 2001-02-12 2001-02-12
US33465401P 2001-11-30 2001-11-30
PCT/EP2002/001106 WO2002064594A2 (en) 2001-02-12 2002-02-04 6-substituted pyrido-pyrimidines

Publications (3)

Publication Number Publication Date
JP2004525896A JP2004525896A (ja) 2004-08-26
JP2004525896A5 true JP2004525896A5 (cg-RX-API-DMAC10.html) 2005-06-09
JP4064818B2 JP4064818B2 (ja) 2008-03-19

Family

ID=26953040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002564525A Expired - Lifetime JP4064818B2 (ja) 2001-02-12 2002-02-04 6−置換ピリド−ピリミジン類

Country Status (31)

Country Link
US (3) US6696566B2 (cg-RX-API-DMAC10.html)
EP (1) EP1361880B1 (cg-RX-API-DMAC10.html)
JP (1) JP4064818B2 (cg-RX-API-DMAC10.html)
KR (1) KR100639772B1 (cg-RX-API-DMAC10.html)
CN (1) CN100376571C (cg-RX-API-DMAC10.html)
AR (1) AR035854A1 (cg-RX-API-DMAC10.html)
AT (1) ATE305303T1 (cg-RX-API-DMAC10.html)
AU (1) AU2002256615B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0207172B8 (cg-RX-API-DMAC10.html)
CA (1) CA2434834C (cg-RX-API-DMAC10.html)
CZ (1) CZ20032416A3 (cg-RX-API-DMAC10.html)
DE (1) DE60206363T2 (cg-RX-API-DMAC10.html)
DK (1) DK1361880T3 (cg-RX-API-DMAC10.html)
ES (1) ES2249574T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20030624B1 (cg-RX-API-DMAC10.html)
HU (1) HU229604B1 (cg-RX-API-DMAC10.html)
IL (2) IL156872A0 (cg-RX-API-DMAC10.html)
JO (1) JO2410B1 (cg-RX-API-DMAC10.html)
MA (1) MA26993A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA03007166A (cg-RX-API-DMAC10.html)
MY (1) MY131518A (cg-RX-API-DMAC10.html)
NO (1) NO326133B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ526961A (cg-RX-API-DMAC10.html)
PA (1) PA8539201A1 (cg-RX-API-DMAC10.html)
PE (1) PE20020976A1 (cg-RX-API-DMAC10.html)
PL (1) PL366918A1 (cg-RX-API-DMAC10.html)
RU (1) RU2269527C2 (cg-RX-API-DMAC10.html)
SK (1) SK11322003A3 (cg-RX-API-DMAC10.html)
WO (1) WO2002064594A2 (cg-RX-API-DMAC10.html)
YU (1) YU63703A (cg-RX-API-DMAC10.html)
ZA (1) ZA200305938B (cg-RX-API-DMAC10.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
SK11322003A3 (en) 2001-02-12 2004-10-05 Hoffmann La Roche 6-Substituted pyrido-pyrimidines
NZ534069A (en) * 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
RU2310657C2 (ru) 2002-04-03 2007-11-20 Ф.Хоффманн-Ля Рош Аг Имидазоконденсированные соединения и фармацевтическая композиция, содержащая их
RU2324695C2 (ru) 2002-08-06 2008-05-20 Ф.Хоффманн-Ля Рош Аг 6-АЛКОКСИПИРИДОПИРИМИДИНЫ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВНОСТЬЮ ИНГИБИТОРОВ КИНАЗЫ МАР р38
WO2004060346A2 (en) 2002-12-30 2004-07-22 Angiotech International Ag Drug delivery from rapid gelling polymer composition
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
ES2279361T3 (es) * 2003-04-16 2007-08-16 F. Hoffmann-La Roche Ag Derivados de (6-(fenoxi)-pirido-3,4-dipirimidin-2-il)-amina como inhibidores de p38 kinasa para el tratamiento de estados inflamatorios tal como artritis reumatoide.
WO2005047284A1 (en) * 2003-11-13 2005-05-26 F. Hoffmann-La Roche Ag Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
EP1831215A1 (en) * 2004-11-23 2007-09-12 Ranbaxy Laboratories Limited Pyrido[2,3-d]pyrimidines as anti-inflamatory agents
US20060142312A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones
WO2006082492A1 (en) * 2005-02-02 2006-08-10 Ranbaxy Laboratories Limited Azabicyclo derivatives as anti-inflammatory agents
JP5198256B2 (ja) * 2005-05-04 2013-05-15 エボテク エージー 縮合複素環式化合物、並びにそれらの組成物及び使用
WO2007009911A1 (en) * 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
AU2006279992A1 (en) * 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
JO2783B1 (en) * 2005-09-30 2014-03-15 نوفارتيس ايه جي Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones
MX2008014908A (es) * 2006-05-26 2009-05-13 Toyama Chemical Co Ltd Compuesto heterociclico nuevo o sal del mismo e intermedio del mismo.
WO2008150260A1 (en) * 2007-06-06 2008-12-11 Gpc Biotech, Inc. 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents
WO2008078249A1 (en) * 2006-12-21 2008-07-03 Ranbaxy Laboratories Limited Anti-inflammatory agents
US8022085B2 (en) 2007-05-07 2011-09-20 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof
CA2690327A1 (en) 2007-06-15 2008-12-18 Thomas P. Cleary A novel process for the preparation of 3-amino-pentan-1,5-diol
US8367671B2 (en) 2008-03-21 2013-02-05 Amgen Inc. Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CN102177161A (zh) * 2008-10-22 2011-09-07 霍夫曼-拉罗奇有限公司 Jnk的嘧啶基吡啶酮抑制剂
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
CN102648200A (zh) 2009-10-09 2012-08-22 亚弗克希斯公司 用于治疗cns病症的8-乙基-6-(芳基)吡啶并[2,3-d]嘧啶-7(8h)-酮
KR101754664B1 (ko) 2009-12-18 2017-07-06 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 치환된 피리도〔2,3-d〕피리미딘-7(8h)-온스 및 이의 치료 용도
WO2016015597A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
CN115105601A (zh) * 2016-06-08 2022-09-27 投资支持有限公司 用于治疗癌症的药物组合
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
PE20190421A1 (es) 2016-08-17 2019-03-19 Support Venture Gmbh Metodo para prevenir o tratar la perdida de la audicion
WO2018132550A1 (en) * 2017-01-11 2018-07-19 The General Hospital Corporation Voltage gated sodium channel imaging agents
KR20190137854A (ko) * 2017-04-04 2019-12-11 스트리킨 아게 안과 질병의 예방 또는 치료 방법
AU2018325442B2 (en) * 2017-08-31 2023-04-13 Dana-Farber Cancer Institute, Inc. Inhibitors of EGFR and/or HER2 and methods of use
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD
WO2020006210A1 (en) * 2018-06-27 2020-01-02 Tufts Medical Center, Inc. Pyridopyrimidine compounds and methods of their use
US20210267983A1 (en) 2018-07-13 2021-09-02 Kinarus Ag Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2022034031A1 (en) 2020-08-11 2022-02-17 Kinarus Ag Methods of preventing or treating covid-19 and related viral diseases or disorders
CN120247910B (zh) * 2025-04-01 2026-05-05 赣南师范大学 一种杂环类化合物及其制备方法、应用和防治肿瘤的药物组合物

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4215216A (en) 1979-04-18 1980-07-29 American Home Products Corporation 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives
US5037826A (en) 1986-10-15 1991-08-06 Schering Corporation 1-substituted naphthyridine and pyridopyrazine derivatives
GB8702758D0 (en) * 1987-02-06 1987-03-11 Wellcome Found Treatment of disease
EP0278686A1 (en) 1987-02-07 1988-08-17 The Wellcome Foundation Limited Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof
HU221425B (en) * 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
WO1993017682A1 (en) 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
TW299333B (cg-RX-API-DMAC10.html) * 1992-12-29 1997-03-01 Takeda Pharm Industry Co Ltd
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
FI971953A7 (fi) * 1994-11-14 1997-05-12 Warner Lambert Co Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6 -aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
IL131618A0 (en) 1997-04-16 2001-01-28 Abbott Lab 5,7-Disubstituted aminopyrido [2,3-D] pyrimidine compounds and their use as adenosine kinase inhibitors
TW458977B (en) * 1997-04-16 2001-10-11 Abbott Lab 6,7-disubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
CN1252069A (zh) 1997-04-16 2000-05-03 艾博特公司 5,6,7-三取代的-4-氨基吡啶并[2,3-d]嘧啶化合物
DE69939168D1 (de) 1998-05-26 2008-09-04 Warner Lambert Co Bicyclische pyrimidine und bicyclische 3,4-dihydropyrimidine als inhibitoren der zellvermehrung
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
EP1078923B1 (en) 1999-08-02 2006-03-08 F. Hoffmann-La Roche Ag Process for the preparation of benzothiophene derivatives
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
AP2002002643A0 (en) * 2000-03-06 2002-12-31 Warner Lambert Co 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
US6518276B2 (en) * 2000-08-31 2003-02-11 Syntex (U.S.A.) Llc 7-oxo-pyridopyrimidines (II)
SK11322003A3 (en) 2001-02-12 2004-10-05 Hoffmann La Roche 6-Substituted pyrido-pyrimidines
NZ534069A (en) * 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer

Similar Documents

Publication Publication Date Title
RU2003125887A (ru) 6-замещенные пиридопиримидины
JP2024532735A5 (cg-RX-API-DMAC10.html)
JP6193922B2 (ja) ハロアルキルヘテロアリールベンズアミド化合物
TWI699359B (zh) 4h-吡咯[3,2-c]吡啶-4-酮衍生物
RU2006134020A (ru) Конденсированные производные пиразола
KR102618971B1 (ko) 7-벤질-4-(2-메틸벤질)-2,4,6,7,8,9-헥사하이드로이미다조 [1,2-a]피리도[3,4-e]피리미딘-5(1h)-온, 그것의 유사체, 및 그것의 염과 치료에서의 그것의 사용 방법
JP2020521741A5 (cg-RX-API-DMAC10.html)
JP2020505395A5 (cg-RX-API-DMAC10.html)
EP4323356A1 (en) Amino-substituted heterocycles for treating cancers with egfr mutations
RU2399620C2 (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
RU2020112759A (ru) Гетероциклические соединения в качестве ингибиторов PAD
US10786492B2 (en) Formylated N-heterocyclic derivatives as FGFR4 inhibitors
JP2018511631A5 (cg-RX-API-DMAC10.html)
JP2010514721A5 (cg-RX-API-DMAC10.html)
JP2012525332A5 (cg-RX-API-DMAC10.html)
JP2010523477A5 (cg-RX-API-DMAC10.html)
UA82199C2 (uk) Похідні заміщеного азаіндолоксооцтового піперазину, що мають противірусну активність, та фармкомпозиція на їх основі
JP2025061387A (ja) 複素環式タンパク質キナーゼ阻害剤を含む製剤
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
JP2004525184A5 (cg-RX-API-DMAC10.html)
JP2004525183A5 (cg-RX-API-DMAC10.html)
RU2006138606A (ru) Ингибиторы киназы
JP2006516643A5 (cg-RX-API-DMAC10.html)
JP2005508942A5 (cg-RX-API-DMAC10.html)
CN106715423A (zh) 氨基取代的异噁唑